Compare DexCom, Inc. (DXCM) vs Nucor Corporation (NUE) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Nucor (NUE) trades at $236.86, up 1.15% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $262.89. Recent earnings beat expectations in Q1 2026 with EPS of $3.23 versus $2.82, though Q4 2025 missed. The company maintains a solid balance sheet with $4.14B in cash and a 53-year dividend growth streak, highlighted by a recent $0.56 dividend declaration. Revenue trends show recovery from 2024 lows, with 2025 revenue at $32.49B and net income of $1.74B.

Outlook is positive due to strong analyst buy ratings (62.5%) and projected earnings growth, but risks include cyclical steel demand and margin pressures from high operating costs. The stock offers value with a P/E of 23.5 and ROE of 11.18%, though investors should monitor Q2 2026 results against a $4.42 EPS estimate for continued momentum.